近日，来自加州大学洛杉矶分校的Antoni Ribas 团队在Nature 上发表题为Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy 的文章。该文章建立了发现肿瘤抗原特异性T细胞的方法，并对比了抗PD-1治疗有反应和无反应患者的CD8+T细胞中针对肿瘤抗原的TCR类型。作者认为在分析免疫检查点阻断剂（immune c...
近日,来自加州大学洛杉矶分校的Antoni Ribas团队在Nature上发表题为Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy的文章。该文章建立了发现肿瘤抗原特异性T细胞的方法,并对比了抗PD-1治疗有反应和无反应患者的CD8+T细胞中针对肿瘤抗原的TCR类型。 作者认为在分析免疫检查点阻断剂(immune checkpoi...
英文题目:Pre-encoded responsiveness to type I interferon in theperipheral immune system defines outcome of PD1 blockade therapy 中文题目:外周免疫系统中对I型干扰素的预编码反应性决定PD1阻断疗法的结果 发表时间:2022年8月 期刊:Nature Immunology IF:31.250 I 型干扰素 (IFN-Is)是抗肿瘤免疫和响应免疫治疗的...
英文题目:Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy 中文题目:外周免疫系统中对I型干扰素的预编码反应性决定PD1阻断疗法的结果 发表时间:2022年8月 期刊:Nature Immunology IF:31.250 I 型干扰素 (IFN-Is)是抗肿瘤免疫和响应免疫治疗...
2.Kline J, Godfrey J, Ansell SM. The immune landscape and response toimmune check- point blockade therapy in lymphoma.Blood. 2020; 135(8):523-533. 3.Roemer MG, Advani RH,Ligon AH, et al. PD- L1 and PD-L2 ...
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR,...
[2] Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L.Immunostimulatory monoclonal antibodies for cancer therapy.Nat Rev Canc 2007;7:95e106.https://doi.org/10.1038/nrc2051. [3] Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint...
Anti--tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD- 1一Ig,0 ].Cytotherapy,2008,10(7):711-719.Anti-tumor i mmunotherapy by blockade of the PD-1/PD-L1pathway with recombinant human PD-1-IgV. Zhang C,Wu S,Xue Xet al. Cytotherapy . 2008...
2、Kamran Kaveh, Feng Fu, Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination, ImmunoInformatics, Volumes 1–2, 2021, 100004, ISSN 2667-1190, https://doi.org/10.1016/j.immuno.2021.100004.3、...
3 PD1 checkpoint blockade improves survival to NME in old mice. (a) Experiments 9 and 11. a. Anti-PD1 intervention and prevention day 7 experimental schematic. (b-e) Experiment 17. b. Young anti-PD1 prevention survival experimental schematic. c. Survival curve measured for 30 days after ...